RecruitingPhase 2NCT04881682
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sponsor
University of Ulm
Enrollment
20 participants
Start Date
May 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a medical device called Immunoadsorption and a biological treatment called Immunoglobulins for people with cidp. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEImmunoadsorption
see arm/group description
BIOLOGICALImmunoglobulins
see arm/group description
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04881682
Related Trials
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT0692000475 locations
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT0709163061 locations
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT0726442623 locations
IVIG vs SCIG in CIDP
NCT055846311 location
Biorepository and Registry for Plasma Exchange Patients
NCT050044931 location